Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
23.96
-1.19 (-4.73%)
At close: Apr 28, 2026, 4:00 PM EDT
23.50
-0.46 (-1.92%)
After-hours: Apr 28, 2026, 5:19 PM EDT
Crescent Biopharma Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Crescent Biopharma stock have an average target of 26.67, with a low estimate of 22 and a high estimate of 35. The average target predicts an increase of 11.31% from the current stock price of 23.96.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 2, 2026.
Analyst Ratings
The average analyst rating for Crescent Biopharma stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $25 → $22 | Strong Buy | Maintains | $25 → $22 | -8.18% | Mar 2, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $35 | Strong Buy | Initiates | $35 | +46.08% | Jan 21, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +4.34% | Aug 27, 2025 |
| Jefferies | Jefferies | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +8.51% | Aug 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +4.34% | Aug 11, 2025 |
Financial Forecast
Revenue This Year
1.46M
from 10.84M
Decreased by -86.56%
Revenue Next Year
5.53M
from 1.46M
Increased by 279.20%
EPS This Year
-3.97
from -12.81
EPS Next Year
-3.88
from -3.97
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 10.5M | 23.6M | ||||||
| Avg | 1.5M | 5.5M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.2% | 1,521.5% | ||||||
| Avg | -86.6% | 279.2% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.30 | -2.49 | ||||||
| Avg | -3.97 | -3.88 | ||||||
| Low | -4.71 | -4.84 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.